Journal Club VL

Timing of Radiotherapy After Radical Prostatectomy (RADICALS-RT) Journal Club - Zachary Klaassen and Christopher Wallis

Details
The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the RADICALS-RT trial Lancet Oncology publication looking at the timing of radiotherapy following radical prostatectomy which aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy wit...

Imaging-Based Prostate Cancer Screening Among BRCA Mutation Carriers - A UroToday Journal Club

Details
Male-carriers of BRCA1/2 gene mutations have an increased risk of prostate cancer (PCa) with a more aggressive phenotype. Current screening-guidelines suggest the use of prostate-specific antigen (PSA) only among BRCA2 carriers. Female carriers have extensive guidelines that include imaging. The study objective was to test the prevalence of prostate cancer among BRCA carriers and examine screening...

Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer A Journal Club on the TRITON 2 Study - Christopher Wallis & Zachary Klaassen

Details
Rucaparib was evaluated as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA gene alteration who had received prior taxane and androgen receptor–directed therapy. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the clinical rationale which led to the exploration of PARP inhibitors in men with advanced prostate can...

(TROG 08.03/ANZUP RAVES) Phase 3 Trial on Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen provide an in-depth review of the Lancet Oncology publication "Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial" in this UroToday Journal Club. Biographies: Christopher J.D. Wallis, MD, Ph.D., Instructor in Urology, Vanderbilt University...

Adjuvant or Early Salvage Radiotherapy for the Treatment of Localized and Locally Advanced Prostate Cancer - The ARTISTIC Collaborative Journal Club - Christopher Wallis ad Zachary Klaassen

Details
There are a number of trials looking at the role of adjuvant radiotherapy in prostate cancer. It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localized or locally advanced prostate cancer. In this Journal Club, Christopher Wallis, MD, Ph.D., and Zachary Klaassen, MD, MSc discuss the recent publication from th...

First-Line Maintenance Avelumab in Patients with advanced Urothelial Carcinoma, A New Standard of Care - JAVELIN Bladder 100 Journal Club - Christopher Wallis & Zachary Klaassen

Details
A new first-line standard of care -- JAVELIN Bladder 100 Platinum-based chemotherapy is currently the standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. In this Journal Club, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc review the JAVELIN Bladder 100 randomized, phase...

Journal Club: Discussing Quality of Life in Patients with Metastatic Prostate Cancer Following Treatment with Cabazitaxel Versus Abiraterone or Enzalutamide - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc, discuss the recently published data (Lancet Oncology) from the CARD trial "Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide." Previously reported from the CARD Study in the NEJM cabazitaxel significantly improved radiographic progression-free survival and o...

Significantly Longer Duration of Overall Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - PROfound Study Journal Club - Zachary Klaassen and Christopher Wallis

Details
In this Journal Club, Zachary Klaassen and Christopher Wallis present on the recently published New England Journal of Medicine article Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, data from the Phase 3 PROfound study. The primary outcome of the study was radiographic progression-free survival in cohort A, which was focused on BRCA1, BRCA2, and ATM mutant patients whi...

Journal Club on Ureteroscopic Doppler Ultrasonography: Mapping Renal Blood Flow From Within the Collecting System- Evangelos Liatsikos and Roshan Patel

Details
Recently published in the Journal of Endourology and the Endourology Society, Jaime Landman, MD, talks with Roshan Patel, MD about his manuscript, titled “Uteroscopic Doppler Ultrasonography, Mapping Renal Blood Flow From Within the Collecting System.” Joined by Dr. Evangelos Liastikos, Dr. Patel notes that while ultrasound has been used in urology since the 1960s, there are limitations to the tec...

Journal Club: The Efficacy and Safety of MitoGel™ (UGN-101) on Ablation of Upper Urinary Tract Urothelial Carcinoma (OLYMPUS) - Zachary Klaassen

Details
Zachary Klaassen, MD, MSc, and Christorpher Wallis, MD, Ph.D., discuss the OLYMPUS study of using UGN-101, a mitomycin-containing reverse thermal gel, for the treatment of Upper Tract Urothelial Carcinoma. The Food and Drug Administration approved mitomycin for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). Efficacy determination was based on OLYMPUS, an ongoing, single-arm...